MATT HOLDING LIMITED is a RNA nanotechnology company discovering and developing novel targeted
nano-RNA therapeutics, next-generation individualized nanomedicines, for cancer therapy using RNA
nanotechnology.
Since April 2016, MATT HOLDING Ltd has started working with its sister companies NANOBIO USA (website
address) and NANOBIO DELIVERY PHARMACEUTICAL, CO (website address), as well as our collaborator,
CENTER FOR NANO RNA TECHNOLOGY at Ohio State University (website address), to develop Nano RNA
therapeutics for treatments of cancers using pRNA-3WJ nanotechnology.
Exciting advances in pRNA-3WJ nanotechnology research have demonstrated the great potential for anticancer
activity of pRNA-3WJ nanoparticles. Several such protocols have been tested in vitro and in animal cancer
models with very promising results for therapeutic applications. In addition, impressive progress has been made
in the treatments of a range of cancers.
The goal of the company is to build upon these advances, to discover, develop and commercialise pRNA-3WJ
therapeutics that are more specific cancer cell targeting, more effective, and no/less side effects, and ultimately to
achieve complete tumor removal.
Our team includes preclinical researchers and clinician scientists from a variety of disciplines, working next to
each other to promote the cross-fertilization of ideas and multidisciplinary interactions. The studies range from
fundamental RNA nanotechnology research to clinical cancer applications. For further information, please contact
us.